REGENERON PHARMACEUTICALS (REGN) Covered Calls

REGENERON PHARMACEUTICALS covered calls Regeneron Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of therapeutics to treat human disorders and conditions.

You can sell covered calls on REGENERON PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for REGN (prices last updated Mon 4:16 PM ET):

REGENERON PHARMACEUTICALS (REGN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
296.60 -5.21 295.00 298.48 707K 23 33B
Covered Calls For REGENERON PHARMACEUTICALS (REGN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jun 15 297.5 8.40 290.08 2.6% 36.5%
Jul 20 295 14.70 283.78 4.0% 23.9%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. The company's products include EYLEA (aflibercept) injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST (rilonacept), which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. The company was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.